Ascendis: Q3 Results Validate The TransCon Platform
Ascendis Pharma has achieved operational profitability, driven by YORVIPATH's rapid adoption and strong Q3 2025 revenues of €213.6 million. ASND's robust cash position (€539 million) and self-sustaining business model eliminate near-term dilution risk and support continued pipeline investment. TransCon platform advances, including SKYTROFA label expansion and TransCon CNP, offer significant growth opportunities, with regulatory risk now mostly administrative.
US FDA extends review of Ascendis Pharma's therapy for children with dwarfism
The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with a rare genetic disorder that causes dwarfism, the company said.
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Chad Fugere Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, Executive VP & Member of Executive Board Jay Wu - Executive VP & President of Ascendis US Aimee Shu - Executive VP & Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Yaron Werber - TD Cowen, Research Division Martin Auster - Raymond James & Associates, Inc., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Yun Zhong - Wedbush Securities Inc., Research Division Charles Ndiaye - Stifel, Nicolaus & Company, Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Maxwell Skor - Morgan Stanley, Research Division Yuxi Dong - Jefferies LLC, Research Division Presentation Operator Good day, and welcome to the Third Quarter 2025 Ascendis Pharma Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to Chad Fugere, Vice President of Investor Relations at Ascendis Pharma.
Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Jan Moller Mikkelsen - President, CEO, Member of Executive Board & Executive Director Jay Donovan Wu - Executive VP & President of Ascendis US Scott T. Smith - CFO, Executive VP & Member of Executive Board Conference Call Participants Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division David Neil Lebowitz - Citigroup Inc., Research Division Derek Christian Archila - Wells Fargo Securities, LLC, Research Division Dingding Shi - Jefferies LLC, Research Division Eliana Rachel Merle - UBS Investment Bank, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Joori Park - Leerink Partners LLC, Research Division Leland James Gershell - Oppenheimer & Co. Inc., Research Division Luca Issi - RBC Capital Markets, Research Division Maxwell Nathan Skor - Morgan Stanley, Research Division Paul Choi - Goldman Sachs Group, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Yaron Benjamin Werber - TD Cowen, Research Division Yun Zhong - Wedbush Securities Inc., Research Division Operator Good day, and thank you for standing by.
Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 29.8% in Ascendis Pharma (ASND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Scott Smith - Executive Vice President and Chief Financial Officer Jan Mikkelsen - President and Chief Executive Officer Sherrie Glass - Chief Business Officer Jay Wu - Executive Vice President and President, U.S. Market Aimee Shu - Executive Vice President and Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark Gartner - Evercore ISI Derek Archila - Wells Fargo Joseph Schwartz - Leerink Partners Paul Choi - Goldman Sachs Li Watsek - Cantor Fitzgerald Ellie Merle - UBS Luca Issi - RBC David Lebowitz - Citi Leland Gershell - Oppenheimer Operator Ladies and gentlemen, thank you for standing by and welcome to Ascendis Pharma First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory
Shares of ASND have fared well during recent market volatility and the downturn in the biotech sector. Setbacks for competitors in PTH (hypoparathyroidism) paves the way for successful Yorvipath launch with long runway to maximize peak sales potential. Management is wisely focusing on applying TransCon technology to rare disease markets while partnering out applications in other areas such as obesity.
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros.
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Chief Business Officer Jay Wu - President, U.S. Market Aimee Shu - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Yaron Werber - TD Cowen Joori Park - Leerink Kelly Shi - Jefferies Ellie Merle - UBS David Lebowitz - Citi Paul Choi - Goldman Sachs Alex Thompson - Stifel Yun Zhong - Wedbush Securities Operator Good day and thank you for standing by. Welcome to the Fourth Quarter and Full Year 2024 Ascendis Pharma Earnings Conference Call.
Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)
TransCon CNP matches BioMarin's Voxzogo for achondroplasia with weekly vs daily dosing; regulatory filings planned for 2025. Commercial products Skytrofa and Yorvipath growing steadily, with Q3 revenue of $62.4M; validates TransCon platform technology. Novo deal for monthly GLP-1 in obesity could be game-changing; includes $285M in milestones plus royalties and expansion options.
